TAS 102

Clinical trials for TAS 102 explained in plain language.

Never miss a new study

Get alerted when new TAS 102 trials appear

Sign up with your email to follow new studies for TAS 102, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet recruiting 1

New combo therapy aims to extend life for elderly esophageal cancer patients

Disease control Not yet recruiting

This study tests a chemotherapy drug (TAS-102) combined with radiation in people aged 65–85 with advanced esophageal cancer. The goal is to find the best dose and see if the combination helps patients live longer. About 45 participants will receive the treatment, followed by a re…

Matched conditions: TAS 102

Phase: PHASE1, PHASE2 • Sponsor: Qianfoshan Hospital • Aim: Disease control

Last updated May 19, 2026 11:47 UTC

TAS 102

Get alerted when new TAS 102 trials appear

New combo therapy aims to extend life for elderly esophageal cancer patients